The earnings call reflected strong growth in the cabozantinib franchise and positive clinical trial results. However, challenges with 340B volume and the decision not to advance a major trial into Phase III created some concerns. Overall, positive developments in key markets and financial metrics outweigh the challenges.

Company Guidance -

Q3 2025

During the Exelixis Second Quarter 2025 Financial Results Conference Call, key financial metrics were highlighted, including a 19% year-over-year increase in U.S. cabozantinib franchise net product revenues, reaching $520 million. The CABOMETYX net product revenues were $518 million, with a gross to net deduction of 30.2%, primarily due to higher 340B volume. The total revenues for the quarter were approximately $568 million, inclusive of $48.2 million in collaboration revenues. The company reported a GAAP net income of $184.8 million, or $0.68 per share basic, and $0.65 per share diluted. Non-GAAP net income was $212.6 million, or $0.78 per share basic and $0.75 per share diluted, excluding $28 million in stock-based compensation. Exelixis repurchased $302 million worth of shares, with $204 million remaining under the current repurchase plan. The company also reiterated its full-year 2025 financial guidance as it assesses additional revenue opportunities in the second half of the year.

Strong Performance of Cabozantinib Franchise

U.S. cabo franchise net product revenues grew 19% year-over-year to $520 million in Q2 2025, compared to $438 million in the second quarter of 2024.

Positive Results from STELLAR-303

The combination of zanzalintinib plus atezolizumab demonstrated a statistically significant improvement in overall survival in the intent-to-treat population for colorectal cancer.

Successful Launch in Neuroendocrine Tumors

CABOMETYX rapidly became the market leader in second-line plus neuroendocrine tumors with approximately 35% new patient share for oral therapies in Q2 2025.

Financial Strength and Share Repurchase

Exelixis reported total revenues of approximately $568 million and repurchased approximately $302 million of the company's shares in Q2 2025.

Exelixis (EXEL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EXEL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	0.68 / -	0.4	―	―	―
Jul 28, 2025	2025 (Q2)	0.67 / 0.75	0.77	-2.60% (-0.02)	―
May 13, 2025	2025 (Q1)	0.36 / 0.62	0.12	416.67% (+0.50)
Feb 11, 2025	2024 (Q4)	0.42 / 0.48	0.27	77.78% (+0.21)
Oct 29, 2024	2024 (Q3)	0.34 / 0.40	0	―
Aug 06, 2024	2024 (Q2)	0.31 / 0.77	0.25	208.00% (+0.52)
Apr 30, 2024	2024 (Q1)	0.22 / 0.12	0.12	0.00% (0.00)
Feb 06, 2024	2023 (Q4)	0.23 / 0.27	-0.09	400.00% (+0.36)
Nov 01, 2023	2023 (Q3)	0.10 / 0.00	0.23	―
Aug 01, 2023	2023 (Q2)	0.15 / 0.25	0.22	13.64% (+0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EXEL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 28, 2025	$44.39	$36.94	-16.78%
May 13, 2025	$36.95	$44.65	+20.84%
Feb 11, 2025	$32.81	$32.80	-0.03%
Oct 29, 2024	$28.73	$32.44	+12.91%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Exelixis (EXEL) report earnings?

Exelixis (EXEL) is schdueled to report earning on Nov 04, 2025, After Close (Confirmed).

What is Exelixis (EXEL) earnings time?

Exelixis (EXEL) earnings time is at Nov 04, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EXEL EPS forecast?

EXEL EPS forecast for the fiscal quarter 2025 (Q3) is 0.68.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing